

WuXi Biologics wins recognition for bioprocessing capabilities

26 March 2019 | News

Over the past eight years, WuXi Biologics has made significant progress in continuous processing and manufacturing, and launched its proprietary WuXiUP platform to enable Biologics manufacturing at competitive costs



WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has received the "Asia's Best CMO of 2018" award from the consulting firm IMAPAC at the recent Asia-Pacific Bioprocessing Excellence Awards. The award was given to WuXi Biologics for the tremendous developments in its bioprocessing capabilities over the past year.

The Asia-Pacific Bioprocessing Excellence Awards aims to celebrate outstanding bioprocessing experts, organizations, and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality.

Over the past eight years, WuXi Biologics has made significant progress in continuous processing and manufacturing, and launched its proprietary WuXiUP platform to enable Biologics manufacturing at competitive costs. With WuXiUP the cell culture has achieved productivity of 2.5g/L/day and 51g/L bioreactor volume in a 20-day process for an Fc-fusion protein, approximately 10 times the productivity of a traditional fed-batch culture.